Anti-Orai1 antibody [EPR3394(2)] (ab111960)


  • Product nameAnti-Orai1 antibody [EPR3394(2)]
    See all Orai1 primary antibodies
  • Description
    Rabbit monoclonal [EPR3394(2)] to Orai1
  • Tested applicationsSuitable for: WBmore details
    Unsuitable for: ICC,IHC-Fr,IHC-P or IP
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide, corresponding to residues from Human Orai1.

  • Positive control
    • Human platelet lysate and Ovary cancer lysate.
  • General notes

    This product is a recombinant rabbit monoclonal antibody.

    Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.



Our Abpromise guarantee covers the use of ab111960 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/10000. Detects a band of approximately 35,50 kDa (predicted molecular weight: 33 kDa).
  • Application notesIs unsuitable for ICC,IHC-Fr,IHC-P or IP.
  • Target

    • FunctionCa(2+) release-activated Ca(2+) (CRAC) channel subunit which mediates Ca(2+) influx following depletion of intracellular Ca(2+) stores and channel activation by the Ca(2+) sensor, STIM1. CRAC channels are the main pathway for Ca(2+) influx in T-cells and promote the immune response to pathogens by activating the transcription factor NFAT.
    • Involvement in diseaseDefects in ORAI1 are the cause of immune dysfunction with T-cell inactivation due to calcium entry defect type 1 (IDTICED1) [MIM:612782]. IDTICED1 is an immune disorder characterized by recurrent infections, impaired T-cell activation and proliferative response, decreased T-cell production of cytokines, and normal lymphocytes counts and serum immunoglobulin levels. In surviving patients ectodermal dysplasia with anhydrosis and non-progressive myopathy may be observed.
    • Sequence similaritiesBelongs to the Orai family.
    • Cellular localizationCell membrane.
    • Information by UniProt
    • Database links
    • Alternative names
      • Calcium release activated calcium channel protein 1 antibody
      • Calcium release activated calcium modulator 1 antibody
      • Calcium release-activated calcium channel protein 1 antibody
      • CRACM 1 antibody
      • CRACM1 antibody
      • CRCM1 antibody
      • CRCM1_HUMAN antibody
      • FLJ14466 antibody
      • Orai 1 antibody
      • ORAI calcium release activated calcium modulator 1 antibody
      • orai1 antibody
      • ORAT1 antibody
      • Protein orai 1 antibody
      • Protein orai-1 antibody
      • TMEM 142A antibody
      • TMEM142A antibody
      • Transmembrane protein 142A antibody
      see all

    Anti-Orai1 antibody [EPR3394(2)] images

    • All lanes : Anti-Orai1 antibody [EPR3394(2)] (ab111960) at 1/1000 dilution

      Lane 1 : Human platelet lysate
      Lane 2 : Human ovary cancer lysate

      Lysates/proteins at 10 µg per lane.

      Predicted band size : 33 kDa

    References for Anti-Orai1 antibody [EPR3394(2)] (ab111960)

    This product has been referenced in:
    • Zhu M  et al. Store-operated Ca(2+) entry regulates glioma cell migration and invasion via modulation of Pyk2 phosphorylation. J Exp Clin Cancer Res 33:98 (2014). Read more (PubMed: 25433371) »

    See 1 Publication for this product

    Product Wall

    The concentration of lot GR100052 is 0.509 mg/ml.

    Thank you for contacting us and your interest in our products. I am pleased to provide the following immunogen information: In order to aid your research we are happy to provide this information to you. However, this immunogen sequence is propr...

    Read More